Rituximab maintenance reduces progression of follicular lymphoma

Patients with previously untreated follicular lymphoma enjoyed a longer period of progression-free survival when treated with rituximab maintenance therapy, according to a large phase III trial known as PRIMA.

COHORT

Patients: 1,217 patients from 25 countries
Time: December 2004 - April 2007

75% were treated with R-CHOP as induction therapy. 1,018 patients responded; so they were randomly assigned either to undergo observation (513) or receive rituximab maintenance therapy (505).

PRIMA was a randomized study sponsored by Groupe d'Etudes de Lymphomes de L'Adulte (GELA) which sought to determine "whether rituximab could improve PFS in patients with stage III or IV follicular lymphoma whose disease was reduced or eliminated by rituximab-based combination chemotherapy."

CONCLUSIONS

According to Gilles Salles, MD one of the study's authors, “Patients who received rituximab maintenance had a significantly reduced risk of lymphoma progression of 50% … rituximab maintenance after induction with rituximab and chemotherapy significantly improves outcomes for follicular lymphoma patients, and we believe it should therefore be considered as the standard of care in first-line follicular lymphoma.”

PUBLICATIONS

These results were presented in a press conference for the upcoming 2010 ASCO Annual Meeting; they have not been published in a peer-reviewed journal yet and until then should be considered preliminary only.

By Ross Bonander

Source: HemOncToday

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...